Takeda Completes its Russian Pharmaceutical Manufacturing Facility

Takeda Completes its Russian Pharmaceutical Manufacturing Facility PR Newswire ZURICH, September 11, 2012 ZURICH, September 11, 2012 /PRNewswire/ -- State-of-the-art facility in Yaroslavl demonstrates Takeda's long-term commitment to the Russian market Plant expected to be fully operational in 2014, supplying high quality tablet and sterile liquid products for the local market €75 million investment Takeda Pharmaceutical International GmbH ("Takeda") today announced the completion of construction at its pharmaceutical manufacturing facility in Yaroslavl, Russia. The Company has invested approximately €75 million in the 224,000m production plant, which is expected to be fully operational by 2014. Takeda was one of the first major international companies to have invested in high quality pharmaceutical manufacturing in thRussia, demonstrating its long-term commitment to the market. Based on sales Takeda is the 7 largest pharmaceutical *company in Russia. According to IMS Health, Russian pharmaceutical sales totaled $14.7 billion in 2011, making it the th11 largest pharmaceutical market in the world. Market sales in Russia/CIS are expected to grow at a compound annual *rate of 11% between 2012 and 2016. Takeda plans to outgrow the market with an annual growth rate of 15% over the same period. The Yaroslavl facility will enable Takeda to meet demand in Russia, initially Cardiomagnyl, Actovegin and Calcium tablets.